.png)
Gene Modifying Immunotherapy for Blood Cancer Market by Type andApplication- Global Industry Analysis & Forecast to 2027
Published On : December 2020 Pages : 152 Category: Biotechnology Report Code : HC1213949
SEGMENTS & REGIONS:
- Regions: North America, Europe, Asia- Pacific, Latin America, Middle East & Africa
Gene Modifying Immunotherapy for Blood Cancer Market by Type(TCR T-cell Therapy,CAR T-cell Therapy)Application (Chronic Lymphocytic Leukemia,Acute Lymphocytic Leukemia,Multiple Myeloma,B Cell Lymphoma)- Global Industry Analysis & Forecast to 2027
Industry Outlook and Trend Analysis
Gene Modifying Immunotherapy for Blood CancerMarket has encountered significant development over the recent years and is anticipated to grow tremendously over the forecast period.Genetic modification immunotherapy for blood cancer is a method that includes hereditary alteration of safe framework T cells.It permits T cells to perceive pitifully communicated antigens in the blood or different organs of the body, for example, tumor cells.
Drivers and Restraints
Top-down and bottom-up approaches are used to validate the global market size market and estimate the market size for company, regions segments, type segments and applications (end users). In the complete market engineering process, both top-down and bottom-up approaches were extensively used, along with several data triangulation methods, to perform market estimation and market forecasting for the overall market segments and sub segments listed in this report. Extensive qualitative and further quantitative analysis is also done from all the numbers arrived at in the complete market engineering process to list key information throughout the report.
Regional Insights
The data for 2021 is an estimate, based on the history data and the integrated view of industry experts, manufacturers, distributors and end users etc.
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- UK
- France
- Russia
- Italy
- Rest of Europe
- Asia-Pacific
- China
- Japan
- South Korea
- India
- Southeast Asia
- Rest of Asia-Pacific
- SouthAmerica
- Brazil
- Argentina
- Columbia
- Rest of South America
- Middle East and Africa
- Saudi Arabia
- UAE
- Egypt
- Nigeria
- South Africa
- Rest of MEA
Competitive Analysis
The major players in the market are profiled in detail in view of qualities, for example, company portfolio, business strategies, financial overview, recent developments, and share of the overall industry.
- Kite Pharma
- Novartis
- Juno Therapeutics
- Ziopharm Oncology
- Cellectis
- Mustang Bio
- Celyad
- Bellicum Pharmaceuticals
- Bluebird Bio
Some of the key questions answered by the report are:
- What was the market size in 2017 and forecast from 2021 to 2027?
- What will be the industry market growth from 2017 to 2027?
- What are the major drivers, restraints, opportunities, challenges, and industry trends and their impact on the market forecast?
- What are the major segments leading the market growth and why?
- Which are the leading players in the market and what are the major strategies adopted by them to sustain the market competition?
Market Classification
· Gene Modifying Immunotherapy for Blood Cancer Market, ByType, Estimates and Forecast, 2017-2027 ($Million)
o TCR T-cell Therapy
o CAR T-cell Therapy
· Gene Modifying Immunotherapy for Blood Cancer Market, ByApplication, Estimates and Forecast, 2017-2027 ($Million)
o Chronic Lymphocytic Leukemia
o Acute Lymphocytic Leukemia
o B Cell Lymphoma
· Gene Modifying Immunotherapy for Blood Cancer Market, By Key Players, Estimates and Forecast, 2017-2027 ($Million)
o Kite Pharma
o Novartis
o Juno Therapeutics
o Ziopharm Oncology
o Cellectis
o Mustang Bio
o Celyad
o Bellicum Pharmaceuticals
o Bluebird Bio
· Gene Modifying Immunotherapy for Blood Cancer Market, By Region, Estimates and Forecast, 2017-2027 ($Million)
o North America
§ North America Gene Modifying Immunotherapy for Blood Cancer Market, By Country
o U.S. Gene Modifying Immunotherapy for Blood Cancer Market
o Canada Gene Modifying Immunotherapy for Blood Cancer Market
o Mexico Gene Modifying Immunotherapy for Blood Cancer Market
o Europe
§ Europe Gene Modifying Immunotherapy for Blood Cancer Market, By Country
· Germany Gene Modifying Immunotherapy for Blood Cancer Market
o UK Gene Modifying Immunotherapy for Blood Cancer Market
o France Gene Modifying Immunotherapy for Blood Cancer Market
o RussiaGene Modifying Immunotherapy for Blood Cancer Market
o Italy Gene Modifying Immunotherapy for Blood Cancer Market
o Rest of Europe Gene Modifying Immunotherapy for Blood Cancer Market
o Asia-Pacific
§ Asia-Pacific Gene Modifying Immunotherapy for Blood Cancer Market, By Country
o ChinaGene Modifying Immunotherapy for Blood Cancer Market
o Japan Gene Modifying Immunotherapy for Blood Cancer Market
o South KoreaGene Modifying Immunotherapy for Blood Cancer Market
o India Gene Modifying Immunotherapy for Blood Cancer Market
o Southeast AsiaGene Modifying Immunotherapy for Blood Cancer Market
o Rest of Asia-Pacific Gene Modifying Immunotherapy for Blood Cancer Market
o South America
§ South AmericaGene Modifying Immunotherapy for Blood Cancer Market
o Brazil Gene Modifying Immunotherapy for Blood Cancer Market
o ArgentinaGene Modifying Immunotherapy for Blood Cancer Market
o ColumbiaGene Modifying Immunotherapy for Blood Cancer Market
o Rest of South America Gene Modifying Immunotherapy for Blood Cancer Market
o Middle East and Africa
§ Middle East and AfricaGene Modifying Immunotherapy for Blood Cancer Market
o Saudi ArabiaGene Modifying Immunotherapy for Blood Cancer Market
o UAEGene Modifying Immunotherapy for Blood Cancer Market
o EgyptGene Modifying Immunotherapy for Blood Cancer Market
o NigeriaGene Modifying Immunotherapy for Blood Cancer Market
o South Africa Gene Modifying Immunotherapy for Blood Cancer Market
o Rest of MEA Gene Modifying Immunotherapy for Blood Cancer Market
Table of Contents:
1. Introduction
1.1. Report Description
2. Executive Summary
2.1. Key Highlights
3. Market Overview
3.1. Introduction
3.1.1. Market Definition
3.1.2. Market Segmentation
3.2. Market Dynamics
3.2.1. Drivers
3.2.2. Restraints
3.2.3. Opportunities
4. Market Analysis by Regions
4.1. North America (United States, Canada and Mexico)
4.1.1. United States Market Status and Outlook (2017-2027)
4.1.2. Canada Market Status and Outlook (2017-2027)
4.1.3. Mexico Market Status and Outlook (2017-2027)
4.2. Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
4.2.1. Germany Market Status and Outlook (2017-2027)
4.2.2. France Market Status and Outlook (2017-2027)
4.2.3. UK Market Status and Outlook (2017-2027)
4.2.4. Russia Market Status and Outlook (2017-2027)
4.2.5. Italy Market Status and Outlook (2017-2027)
4.2.6. Rest of Europe Market Status and Outlook (2017-2027)
4.3. Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Rest of Asia-Pacific)
4.3.1. China Market Status and Outlook (2017-2027)
4.3.2. Japan Market Status and Outlook (2017-2027)
4.3.3. Korea Market Status and Outlook (2017-2027)
4.3.4. India Market Status and Outlook (2017-2027)
4.3.5. Southeast Asia Market Status and Outlook (2017-2027)
4.3.6. Rest of Asia-Pacific Market Status and Outlook (2017-2027)
4.4. South America (Brazil, Argentina, Columbia and Rest of South America)
4.4.1. Brazil Market Status and Outlook (2017-2027)
4.4.2. Argentina Market Status and Outlook (2017-2027)
4.4.3. Columbia Market Status and Outlook (2017-2027)
4.4.4. Rest of South America Market Status and Outlook (2017-2027)
4.5. Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa and Rest of MEA)
4.5.1. Saudi Arabia Market Status and Outlook (2017-2027)
4.5.2. United Arab Emirates Market Status and Outlook (2017-2027)
4.5.3. Egypt Market Status and Outlook (2017-2027)
4.5.4. Nigeria Market Status and Outlook (2017-2027)
4.5.5. South Africa Market Status and Outlook (2017-2027)
4.5.6. Turkey Market Status and Outlook (2017-2027)
4.5.7. Rest of Middle East and Africa Market Status and Outlook (2017-2027)
5. Gene Modifying Immunotherapy For Blood Cancer Market, By Type
5.1. Introduction
5.2. Global Gene Modifying Immunotherapy For Blood Cancer Revenue and Market Share by Type (2017-2021)
5.2.1. Global Gene Modifying Immunotherapy For Blood Cancer Revenue and Revenue Share by Type (2017-2021)
5.3. TCR T-cell Therapy
5.3.1. Global TCR T-cell Therapy Revenue and Growth Rate (2017-2021)
5.4. CAR T-cell Therapy
5.4.1. Global CAR T-cell Therapy Revenue and Growth Rate (2017-2021)
6. Gene Modifying Immunotherapy For Blood Cancer Market, By Application
6.1. Introduction
6.2. Global Gene Modifying Immunotherapy For Blood Cancer Revenue and Market Share by Application (2017-2021)
6.2.1. Global Gene Modifying Immunotherapy For Blood Cancer Revenue and Revenue Share by Application (2017-2021)
6.3. Chronic Lymphocytic Leukemia
6.3.1. Global Chronic Lymphocytic Leukemia Revenue and Growth Rate (2017-2021)
6.4. Acute Lymphocytic Leukemia
6.4.1. Global Acute Lymphocytic Leukemia Revenue and Growth Rate (2017-2021)
6.5. Multiple Myeloma
6.5.1. Global Multiple Myeloma Revenue and Growth Rate (2017-2021)
6.6. B Cell Lymphoma
6.6.1. Global B Cell Lymphoma Revenue and Growth Rate (2017-2021)
7. Gene Modifying Immunotherapy For Blood Cancer Market, By Region
7.1. Introduction
7.2. Global Gene Modifying Immunotherapy For Blood Cancer Revenue and Market Share by Regions
7.2.1. Global Gene Modifying Immunotherapy For Blood Cancer Revenue by Regions (2017-2021)
7.3. North America Gene Modifying Immunotherapy For Blood Cancer by Countries
7.3.1. North America Gene Modifying Immunotherapy For Blood Cancer Revenue and Growth Rate (2017-2021)
7.3.2. North America Gene Modifying Immunotherapy For Blood Cancer Revenue (Million USD) by Countries (2017-2021)
7.3.3. United States
7.3.3.1. United States Gene Modifying Immunotherapy For Blood Cancer Revenue (Millions USD) and Growth Rate (2017-2021)
7.3.4. Canada
7.3.4.1. Canada Gene Modifying Immunotherapy For Blood Cancer Revenue (Millions USD) and Growth Rate (2017-2021)
7.3.5. Mexico
7.3.5.1. Mexico Gene Modifying Immunotherapy For Blood Cancer Revenue (Millions USD) and Growth Rate (2017-2021)
7.4. Europe Gene Modifying Immunotherapy For Blood Cancer by Countries
7.4.1. Europe Gene Modifying Immunotherapy For Blood Cancer Revenue and Growth Rate (2017-2021)
7.4.2. Europe Gene Modifying Immunotherapy For Blood Cancer Revenue (Million USD) by Countries (2017-2021)
7.4.3. Germany
7.4.3.1. Germany Gene Modifying Immunotherapy For Blood Cancer Revenue (Millions USD) and Growth Rate (2017-2021)
7.4.4. France
7.4.4.1. France Gene Modifying Immunotherapy For Blood Cancer Revenue (Millions USD) and Growth Rate (2017-2021)
7.4.5. UK
7.4.5.1. UK Gene Modifying Immunotherapy For Blood Cancer Revenue (Millions USD) and Growth Rate (2017-2021)
7.4.6. Russia
7.4.6.1. Russia Gene Modifying Immunotherapy For Blood Cancer Revenue (Millions USD) and Growth Rate (2017-2021)
7.4.7. Italy
7.4.7.1. Italy Gene Modifying Immunotherapy For Blood Cancer Revenue (Millions USD) and Growth Rate (2017-2021)
7.4.8. Rest of Europe
7.4.8.1. Rest of Europe Gene Modifying Immunotherapy For Blood Cancer Revenue (Millions USD) and Growth Rate (2017-2021)
7.5. Asia-Pacific Gene Modifying Immunotherapy For Blood Cancer by Countries
7.5.1. Asia-Pacific Gene Modifying Immunotherapy For Blood Cancer Revenue and Growth Rate (2017-2021)
7.5.2. Asia-Pacific Gene Modifying Immunotherapy For Blood Cancer Revenue (Million USD) by Countries (2017-2021)
7.5.3. China
7.5.3.1. China Gene Modifying Immunotherapy For Blood Cancer Revenue (Millions USD) and Growth Rate (2017-2021)
7.5.4. Japan
7.5.4.1. Japan Gene Modifying Immunotherapy For Blood Cancer Revenue (Millions USD) and Growth Rate (2017-2021)
7.5.5. Korea
7.5.5.1. Korea Gene Modifying Immunotherapy For Blood Cancer Revenue (Millions USD) and Growth Rate (2017-2021)
7.5.6. India
7.5.6.1. India Gene Modifying Immunotherapy For Blood Cancer Revenue (Millions USD) and Growth Rate (2017-2021)
7.5.7. Southeast Asia
7.5.7.1. Southeast Asia Gene Modifying Immunotherapy For Blood Cancer Revenue (Millions USD) and Growth Rate (2017-2021)
7.5.8. Rest of Asia-Pacific
7.5.8.1. Rest of Asia-Pacific Gene Modifying Immunotherapy For Blood Cancer Revenue (Millions USD) and Growth Rate (2017-2021)
7.6. South America Gene Modifying Immunotherapy For Blood Cancer by Countries
7.6.1. South America Gene Modifying Immunotherapy For Blood Cancer Revenue and Growth Rate (2017-2021)
7.6.2. South America Gene Modifying Immunotherapy For Blood Cancer Revenue (Million USD) by Countries (2017-2021)
7.6.3. Brazil
7.6.3.1. Brazil Gene Modifying Immunotherapy For Blood Cancer Revenue (Millions USD) and Growth Rate (2017-2021)
7.6.4. Argentina
7.6.4.1. Argentina Gene Modifying Immunotherapy For Blood Cancer Revenue (Millions USD) and Growth Rate (2017-2021)
7.6.5. Columbia
7.6.5.1. Columbia Gene Modifying Immunotherapy For Blood Cancer Revenue (Millions USD) and Growth Rate (2017-2021)
7.6.6. Rest of South America
7.6.6.1. Rest of South America Gene Modifying Immunotherapy For Blood Cancer Revenue (Millions USD) and Growth Rate (2017-2021)
7.7. Middle East and Africa Gene Modifying Immunotherapy For Blood Cancer by Countries
7.7.1. Middle East and Africa Gene Modifying Immunotherapy For Blood Cancer Revenue and Growth Rate (2017-2021)
7.7.2. Middle East and Africa Gene Modifying Immunotherapy For Blood Cancer Revenue (Million USD) by Countries (2017-2021)
7.7.3. Saudi Arabia
7.7.3.1. Saudi Arabia Gene Modifying Immunotherapy For Blood Cancer Revenue (Millions USD) and Growth Rate (2017-2021)
7.7.4. United Arab Emirates
7.7.4.1. United Arab Emirates Gene Modifying Immunotherapy For Blood Cancer Revenue (Millions USD) and Growth Rate (2017-2021)
7.7.5. Egypt
7.7.5.1. Egypt Gene Modifying Immunotherapy For Blood Cancer Revenue (Millions USD) and Growth Rate (2017-2021)
7.7.6. Nigeria
7.7.6.1. Nigeria Gene Modifying Immunotherapy For Blood Cancer Revenue (Millions USD) and Growth Rate (2017-2021)
7.7.7. South Africa
7.7.7.1. South Africa Gene Modifying Immunotherapy For Blood Cancer Revenue (Millions USD) and Growth Rate (2017-2021)
7.7.8. Turkey
7.7.8.1. Turkey Gene Modifying Immunotherapy For Blood Cancer Revenue (Millions USD) and Growth Rate (2017-2021)
7.7.9. Rest of Middle East and Africa
7.7.9.1. Rest of Middle East and Africa Gene Modifying Immunotherapy For Blood Cancer Revenue (Millions USD) and Growth Rate (2017-2021)
8. Company Profiles
8.1. Kite Pharma
8.1.1. Business Overview
8.1.2. Service Portfolio
8.1.3. Strategic Developments
8.1.4. Financial Overview
8.2. Novartis
8.2.1. Business Overview
8.2.2. Service Portfolio
8.2.3. Strategic Developments
8.2.4. Financial Overview
8.3. Juno Therapeutics
8.3.1. Business Overview
8.3.2. Service Portfolio
8.3.3. Strategic Developments
8.3.4. Financial Overview
8.4. Ziopharm Oncology
8.4.1. Business Overview
8.4.2. Service Portfolio
8.4.3. Strategic Developments
8.4.4. Financial Overview
8.5. Cellectis
8.5.1. Business Overview
8.5.2. Service Portfolio
8.5.3. Strategic Developments
8.5.4. Financial Overview
8.6. Mustang Bio
8.6.1. Business Overview
8.6.2. Service Portfolio
8.6.3. Strategic Developments
8.6.4. Financial Overview
8.7. Celyad
8.7.1. Business Overview
8.7.2. Service Portfolio
8.7.3. Strategic Developments
8.7.4. Financial Overview
8.8. Bellicum Pharmaceuticals
8.8.1. Business Overview
8.8.2. Service Portfolio
8.8.3. Strategic Developments
8.8.4. Financial Overview
8.9. Bluebird Bio
8.9.1. Business Overview
8.9.2. Service Portfolio
8.9.3. Strategic Developments
8.9.4. Financial Overview
9. Gene Modifying Immunotherapy For Blood Cancer Market Forecast (2022-2027)
9.1. Global Gene Modifying Immunotherapy For Blood Cancer Revenue (Millions USD) and Growth Rate (2022-2027)
9.2. Gene Modifying Immunotherapy For Blood Cancer Market Forecast by Regions (2022-2027)
9.2.1. North America Gene Modifying Immunotherapy For Blood Cancer Market Forecast (2022-2027)
9.2.1.1. United States Gene Modifying Immunotherapy For Blood Cancer Market Forecast (2022-2027)
9.2.1.2. Canada Gene Modifying Immunotherapy For Blood Cancer Market Forecast (2022-2027)
9.2.1.3. Mexico Gene Modifying Immunotherapy For Blood Cancer Market Forecast (2022-2027)
9.2.2. Europe Gene Modifying Immunotherapy For Blood Cancer Market Forecast (2022-2027)
9.2.2.1. Germany Gene Modifying Immunotherapy For Blood Cancer Market Forecast (2022-2027)
9.2.2.2. France Gene Modifying Immunotherapy For Blood Cancer Market Forecast (2022-2027)
9.2.2.3. UK Gene Modifying Immunotherapy For Blood Cancer Market Forecast (2022-2027)
9.2.2.4. Russia Gene Modifying Immunotherapy For Blood Cancer Market Forecast (2022-2027)
9.2.2.5. Italy Gene Modifying Immunotherapy For Blood Cancer Market Forecast (2022-2027)
9.2.2.6. Rest of Europe Gene Modifying Immunotherapy For Blood Cancer Market Forecast (2022-2027)
9.2.3. Asia-Pacific Gene Modifying Immunotherapy For Blood Cancer Market Forecast (2022-2027)
9.2.3.1. China Gene Modifying Immunotherapy For Blood Cancer Market Forecast (2022-2027)
9.2.3.2. Japan Gene Modifying Immunotherapy For Blood Cancer Market Forecast (2022-2027)
9.2.3.3. Korea Gene Modifying Immunotherapy For Blood Cancer Market Forecast (2022-2027)
9.2.3.4. India Gene Modifying Immunotherapy For Blood Cancer Market Forecast (2022-2027)
9.2.3.5. Southeast Asia Gene Modifying Immunotherapy For Blood Cancer Market Forecast (2022-2027)
9.2.3.6. Rest of Asia-Pacific Gene Modifying Immunotherapy For Blood Cancer Market Forecast (2022-2027)
9.2.4. South America Gene Modifying Immunotherapy For Blood Cancer Market Forecast (2022-2027)
9.2.4.1. Brazil Gene Modifying Immunotherapy For Blood Cancer Market Forecast (2022-2027)
9.2.4.2. Argentina Gene Modifying Immunotherapy For Blood Cancer Market Forecast (2022-2027)
9.2.4.3. Columbia Gene Modifying Immunotherapy For Blood Cancer Market Forecast (2022-2027)
9.2.4.4. Rest of South America Gene Modifying Immunotherapy For Blood Cancer Market Forecast (2022-2027)
9.2.5. Middle East and Africa Gene Modifying Immunotherapy For Blood Cancer Market Forecast (2022-2027)
9.2.5.1. Saudi Arabia Gene Modifying Immunotherapy For Blood Cancer Market Forecast (2022-2027)
9.2.5.2. United Arab Emirates Gene Modifying Immunotherapy For Blood Cancer Market Forecast (2022-2027)
9.2.5.3. Egypt Gene Modifying Immunotherapy For Blood Cancer Market Forecast (2022-2027)
9.2.5.4. Nigeria Gene Modifying Immunotherapy For Blood Cancer Market Forecast (2022-2027)
9.2.5.5. South Africa Gene Modifying Immunotherapy For Blood Cancer Market Forecast (2022-2027)
9.2.5.6. Turkey Gene Modifying Immunotherapy For Blood Cancer Market Forecast (2022-2027)
9.2.5.7. Rest of Middle East and Africa Gene Modifying Immunotherapy For Blood Cancer Market Forecast (2022-2027)
9.3. Gene Modifying Immunotherapy For Blood Cancer Market Forecast by Type (2022-2027)
9.3.1. Gene Modifying Immunotherapy For Blood Cancer Forecast by Type (2022-2027)
9.3.2. Gene Modifying Immunotherapy For Blood Cancer Market Share Forecast by Type (2022-2027)
9.4. Gene Modifying Immunotherapy For Blood Cancer Market Forecast by Application (2022-2027)
9.4.1. Gene Modifying Immunotherapy For Blood Cancer Forecast by Application (2022-2027)
9.4.2. Gene Modifying Immunotherapy For Blood Cancer Market Share Forecast by Application (2022-2027)
List of Tables
List of Tables and Figures:
Figure United States Gene Modifying Immunotherapy For Blood Cancer Revenue (Million USD) and Growth Rate (2017-2027)
Figure Canada Gene Modifying Immunotherapy For Blood Cancer Revenue (Million USD) and Growth Rate (2017-2027)
Figure Mexico Gene Modifying Immunotherapy For Blood Cancer Revenue (Million USD) and Growth Rate (2017-2027)
Figure Germany Gene Modifying Immunotherapy For Blood Cancer Revenue (Million USD) and Growth Rate (2017-2027)
Figure France Gene Modifying Immunotherapy For Blood Cancer Revenue (Million USD) and Growth Rate (2017-2027)
Figure UK Gene Modifying Immunotherapy For Blood Cancer Revenue (Million USD) and Growth Rate (2017-2027)
Figure Russia Gene Modifying Immunotherapy For Blood Cancer Revenue (Million USD) and Growth Rate (2017-2027)
Figure Italy Gene Modifying Immunotherapy For Blood Cancer Revenue (Million USD) and Growth Rate (2017-2027)
Figure Rest of Europe Gene Modifying Immunotherapy For Blood Cancer Revenue (Million USD) and Growth Rate (2017-2027)
Figure China Gene Modifying Immunotherapy For Blood Cancer Revenue (Million USD) and Growth Rate (2017-2027)
Figure Japan Gene Modifying Immunotherapy For Blood Cancer Revenue (Million USD) and Growth Rate (2017-2027)
Figure Korea Gene Modifying Immunotherapy For Blood Cancer Revenue (Million USD) and Growth Rate (2017-2027)
Figure India Gene Modifying Immunotherapy For Blood Cancer Revenue (Million USD) and Growth Rate (2017-2027)
Figure Southeast Asia Gene Modifying Immunotherapy For Blood Cancer Revenue (Million USD) and Growth Rate (2017-2027)
Figure Rest of Asia-Pacific Gene Modifying Immunotherapy For Blood Cancer Revenue (Million USD) and Growth Rate (2017-2027)
Figure Brazil Gene Modifying Immunotherapy For Blood Cancer Revenue (Million USD) and Growth Rate (2017-2027)
Figure Argentina Gene Modifying Immunotherapy For Blood Cancer Revenue (Million USD) and Growth Rate (2017-2027)
Figure Columbia Gene Modifying Immunotherapy For Blood Cancer Revenue (Million USD) and Growth Rate (2017-2027)
Figure Rest of South America Gene Modifying Immunotherapy For Blood Cancer Revenue (Million USD) and Growth Rate (2017-2027)
Figure Saudi Arabia Gene Modifying Immunotherapy For Blood Cancer Revenue (Million USD) and Growth Rate (2017-2027)
Figure United Arab Emirates Gene Modifying Immunotherapy For Blood Cancer Revenue (Million USD) and Growth Rate (2017-2027)
Figure Egypt Gene Modifying Immunotherapy For Blood Cancer Revenue (Million USD) and Growth Rate (2017-2027)
Figure Nigeria Gene Modifying Immunotherapy For Blood Cancer Revenue (Million USD) and Growth Rate (2017-2027)
Figure South Africa Gene Modifying Immunotherapy For Blood Cancer Revenue (Million USD) and Growth Rate (2017-2027)
Figure Turkey Gene Modifying Immunotherapy For Blood Cancer Revenue (Million USD) and Growth Rate (2017-2027)
Figure Rest of Middle East and Africa Gene Modifying Immunotherapy For Blood Cancer Revenue (Million USD) and Growth Rate (2017-2027)
Table Global Gene Modifying Immunotherapy For Blood Cancer Revenue and Revenue Share by Type (2017-2019)
Figure Global TCR T-cell Therapy Revenue and Growth Rate (2017-2019)
Figure Global CAR T-cell Therapy Revenue and Growth Rate (2017-2019)
Table Global Gene Modifying Immunotherapy For Blood Cancer Revenue and Revenue Share by Application (2017-2019)
Figure Global Chronic Lymphocytic Leukemia Revenue and Growth Rate (2017-2019)
Figure Global Acute Lymphocytic Leukemia Revenue and Growth Rate (2017-2019)
Figure Global Multiple Myeloma Revenue and Growth Rate (2017-2019)
Figure Global B Cell Lymphoma Revenue and Growth Rate (2017-2019)
Table Global Gene Modifying Immunotherapy For Blood Cancer Revenue by Regions (2017-2019)
Figure North America Gene Modifying Immunotherapy For Blood Cancer Growth Rate (2017-2019)
Figure North America Gene Modifying Immunotherapy For Blood Cancer Revenue and Growth Rate (2017-2019)
Figure North America Gene Modifying Immunotherapy For Blood Cancer by Countries (2017-2019)
Figure North America Gene Modifying Immunotherapy For Blood Cancer Revenue (Million USD) by Countries (2017-2019)
Figure United States Gene Modifying Immunotherapy For Blood Cancer Growth Rate (2017-2019)
Figure United States Gene Modifying Immunotherapy For Blood Cancer Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Canada Gene Modifying Immunotherapy For Blood Cancer Growth Rate (2017-2019)
Figure Canada Gene Modifying Immunotherapy For Blood Cancer Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Mexico Gene Modifying Immunotherapy For Blood Cancer Growth Rate (2017-2019)
Figure Mexico Gene Modifying Immunotherapy For Blood Cancer Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Europe Gene Modifying Immunotherapy For Blood Cancer Growth Rate (2017-2019)
Figure Europe Gene Modifying Immunotherapy For Blood Cancer Revenue and Growth Rate (2017-2019)
Figure Europe Gene Modifying Immunotherapy For Blood Cancer by Countries (2017-2019)
Figure Europe Gene Modifying Immunotherapy For Blood Cancer Revenue (Million USD) by Countries (2017-2019)
Figure Germany Gene Modifying Immunotherapy For Blood Cancer Growth Rate (2017-2019)
Figure Germany Gene Modifying Immunotherapy For Blood Cancer Revenue (Millions USD) and Growth Rate (2017-2019)
Figure France Gene Modifying Immunotherapy For Blood Cancer Growth Rate (2017-2019)
Figure France Gene Modifying Immunotherapy For Blood Cancer Revenue (Millions USD) and Growth Rate (2017-2019)
Figure UK Gene Modifying Immunotherapy For Blood Cancer Growth Rate (2017-2019)
Figure UK Gene Modifying Immunotherapy For Blood Cancer Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Russia Gene Modifying Immunotherapy For Blood Cancer Growth Rate (2017-2019)
Figure Russia Gene Modifying Immunotherapy For Blood Cancer Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Italy Gene Modifying Immunotherapy For Blood Cancer Growth Rate (2017-2019)
Figure Italy Gene Modifying Immunotherapy For Blood Cancer Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Rest of Europe Gene Modifying Immunotherapy For Blood Cancer Growth Rate (2017-2019)
Figure Rest of Europe Gene Modifying Immunotherapy For Blood Cancer Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Asia-Pacific Gene Modifying Immunotherapy For Blood Cancer Growth Rate (2017-2019)
Figure Asia-Pacific Gene Modifying Immunotherapy For Blood Cancer Revenue and Growth Rate (2017-2019)
Figure Asia-Pacific Gene Modifying Immunotherapy For Blood Cancer by Countries (2017-2019)
Figure Asia-Pacific Gene Modifying Immunotherapy For Blood Cancer Revenue (Million USD) by Countries (2017-2019)
Figure China Gene Modifying Immunotherapy For Blood Cancer Growth Rate (2017-2019)
Figure China Gene Modifying Immunotherapy For Blood Cancer Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Japan Gene Modifying Immunotherapy For Blood Cancer Growth Rate (2017-2019)
Figure Japan Gene Modifying Immunotherapy For Blood Cancer Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Korea Gene Modifying Immunotherapy For Blood Cancer Growth Rate (2017-2019)
Figure Korea Gene Modifying Immunotherapy For Blood Cancer Revenue (Millions USD) and Growth Rate (2017-2019)
Figure India Gene Modifying Immunotherapy For Blood Cancer Growth Rate (2017-2019)
Figure India Gene Modifying Immunotherapy For Blood Cancer Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Southeast Asia Gene Modifying Immunotherapy For Blood Cancer Growth Rate (2017-2019)
Figure Southeast Asia Gene Modifying Immunotherapy For Blood Cancer Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Rest of Asia-Pacific Gene Modifying Immunotherapy For Blood Cancer Growth Rate (2017-2019)
Figure Rest of Asia-Pacific Gene Modifying Immunotherapy For Blood Cancer Revenue (Millions USD) and Growth Rate (2017-2019)
Figure South America Gene Modifying Immunotherapy For Blood Cancer Growth Rate (2017-2019)
Figure South America Gene Modifying Immunotherapy For Blood Cancer Revenue and Growth Rate (2017-2019)
Figure South America Gene Modifying Immunotherapy For Blood Cancer by Countries (2017-2019)
Figure South America Gene Modifying Immunotherapy For Blood Cancer Revenue (Million USD) by Countries (2017-2019)
Figure Brazil Gene Modifying Immunotherapy For Blood Cancer Growth Rate (2017-2019)
Figure Brazil Gene Modifying Immunotherapy For Blood Cancer Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Argentina Gene Modifying Immunotherapy For Blood Cancer Growth Rate (2017-2019)
Figure Argentina Gene Modifying Immunotherapy For Blood Cancer Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Columbia Gene Modifying Immunotherapy For Blood Cancer Growth Rate (2017-2019)
Figure Columbia Gene Modifying Immunotherapy For Blood Cancer Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Rest of South America Gene Modifying Immunotherapy For Blood Cancer Growth Rate (2017-2019)
Figure Rest of South America Gene Modifying Immunotherapy For Blood Cancer Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Middle East and Africa Gene Modifying Immunotherapy For Blood Cancer Growth Rate (2017-2019)
Figure Middle East and Africa Gene Modifying Immunotherapy For Blood Cancer Revenue and Growth Rate (2017-2019)
Figure Middle East and Africa Gene Modifying Immunotherapy For Blood Cancer by Countries (2017-2019)
Figure Middle East and Africa Gene Modifying Immunotherapy For Blood Cancer Revenue (Million USD) by Countries (2017-2019)
Figure Saudi Arabia Gene Modifying Immunotherapy For Blood Cancer Growth Rate (2017-2019)
Figure Saudi Arabia Gene Modifying Immunotherapy For Blood Cancer Revenue (Millions USD) and Growth Rate (2017-2019)
Figure United Arab Emirates Gene Modifying Immunotherapy For Blood Cancer Growth Rate (2017-2019)
Figure United Arab Emirates Gene Modifying Immunotherapy For Blood Cancer Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Egypt Gene Modifying Immunotherapy For Blood Cancer Growth Rate (2017-2019)
Figure Egypt Gene Modifying Immunotherapy For Blood Cancer Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Nigeria Gene Modifying Immunotherapy For Blood Cancer Growth Rate (2017-2019)
Figure Nigeria Gene Modifying Immunotherapy For Blood Cancer Revenue (Millions USD) and Growth Rate (2017-2019)
Figure South Africa Gene Modifying Immunotherapy For Blood Cancer Growth Rate (2017-2019)
Figure South Africa Gene Modifying Immunotherapy For Blood Cancer Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Turkey Gene Modifying Immunotherapy For Blood Cancer Growth Rate (2017-2019)
Figure Turkey Gene Modifying Immunotherapy For Blood Cancer Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Rest of Middle East and Africa Gene Modifying Immunotherapy For Blood Cancer Growth Rate (2017-2019)
Figure Rest of Middle East and Africa Gene Modifying Immunotherapy For Blood Cancer Revenue (Millions USD) and Growth Rate (2017-2019)
Table Kite Pharma Gene Modifying Immunotherapy For Blood Cancer Financial Overview
Table Novartis Gene Modifying Immunotherapy For Blood Cancer Financial Overview
Table Juno Therapeutics Gene Modifying Immunotherapy For Blood Cancer Financial Overview
Table Ziopharm Oncology Gene Modifying Immunotherapy For Blood Cancer Financial Overview
Table Cellectis Gene Modifying Immunotherapy For Blood Cancer Financial Overview
Table Mustang Bio Gene Modifying Immunotherapy For Blood Cancer Financial Overview
Table Celyad Gene Modifying Immunotherapy For Blood Cancer Financial Overview
Table Bellicum Pharmaceuticals Gene Modifying Immunotherapy For Blood Cancer Financial Overview
Table Bluebird Bio Gene Modifying Immunotherapy For Blood Cancer Financial Overview
Figure Global Gene Modifying Immunotherapy For Blood Cancer Revenue (Millions USD) and Growth Rate (2019-2027)
Table Gene Modifying Immunotherapy For Blood Cancer Market Forecast by Regions (2019-2027)
Figure North America Gene Modifying Immunotherapy For Blood Cancer Market Forecast (2019-2027)
Figure United States Gene Modifying Immunotherapy For Blood Cancer Market Forecast (2019-2027)
Figure Canada Gene Modifying Immunotherapy For Blood Cancer Market Forecast (2019-2027)
Figure Mexico Gene Modifying Immunotherapy For Blood Cancer Market Forecast (2019-2027)
Figure Europe Gene Modifying Immunotherapy For Blood Cancer Market Forecast (2019-2027)
Figure Germany Gene Modifying Immunotherapy For Blood Cancer Market Forecast (2019-2027)
Figure France Gene Modifying Immunotherapy For Blood Cancer Market Forecast (2019-2027)
Figure UK Gene Modifying Immunotherapy For Blood Cancer Market Forecast (2019-2027)
Figure Russia Gene Modifying Immunotherapy For Blood Cancer Market Forecast (2019-2027)
Figure Italy Gene Modifying Immunotherapy For Blood Cancer Market Forecast (2019-2027)
Figure Rest of Europe Gene Modifying Immunotherapy For Blood Cancer Market Forecast (2019-2027)
Figure Asia-Pacific Gene Modifying Immunotherapy For Blood Cancer Market Forecast (2019-2027)
Figure China Gene Modifying Immunotherapy For Blood Cancer Market Forecast (2019-2027)
Figure Japan Gene Modifying Immunotherapy For Blood Cancer Market Forecast (2019-2027)
Figure Korea Gene Modifying Immunotherapy For Blood Cancer Market Forecast (2019-2027)
Figure India Gene Modifying Immunotherapy For Blood Cancer Market Forecast (2019-2027)
Figure Southeast Asia Gene Modifying Immunotherapy For Blood Cancer Market Forecast (2019-2027)
Figure Rest of Asia-Pacific Gene Modifying Immunotherapy For Blood Cancer Market Forecast (2019-2027)
Figure South America Gene Modifying Immunotherapy For Blood Cancer Market Forecast (2019-2027)
Figure Brazil Gene Modifying Immunotherapy For Blood Cancer Market Forecast (2019-2027)
Figure Argentina Gene Modifying Immunotherapy For Blood Cancer Market Forecast (2019-2027)
Figure Columbia Gene Modifying Immunotherapy For Blood Cancer Market Forecast (2019-2027)
Figure Rest of South America Gene Modifying Immunotherapy For Blood Cancer Market Forecast (2019-2027)
Figure Middle East and Africa Gene Modifying Immunotherapy For Blood Cancer Market Forecast (2019-2027)
Figure Saudi Arabia Gene Modifying Immunotherapy For Blood Cancer Market Forecast (2019-2027)
Figure United Arab Emirates Gene Modifying Immunotherapy For Blood Cancer Market Forecast (2019-2027)
Figure Egypt Gene Modifying Immunotherapy For Blood Cancer Market Forecast (2019-2027)
Figure Nigeria Gene Modifying Immunotherapy For Blood Cancer Market Forecast (2019-2027)
Figure South Africa Gene Modifying Immunotherapy For Blood Cancer Market Forecast (2019-2027)
Figure Turkey Gene Modifying Immunotherapy For Blood Cancer Market Forecast (2019-2027)
Figure Rest of Middle East and Africa Gene Modifying Immunotherapy For Blood Cancer Market Forecast (2019-2027)
Figure Global Gene Modifying Immunotherapy For Blood Cancer Forecast by Type (2019-2027)
Figure Global Gene Modifying Immunotherapy For Blood Cancer Market Share Forecast by Type (2019-2027)
Figure Global Gene Modifying Immunotherapy For Blood Cancer Forecast by Type (2019-2027)
Figure Global Gene Modifying Immunotherapy For Blood Cancer Forecast by Application (2019-2027)
Figure Global Gene Modifying Immunotherapy For Blood Cancer Market Share Forecast by Application (2019-2027)
Figure Global Gene Modifying Immunotherapy For Blood Cancer Forecast by Application (2019-2027)
Please Note: Data related to the Companies are subject to Availability.
Research Methodology
We use both primary as well as secondary research for our market surveys, estimates and for developing forecast. Our research process commence by analyzing the problem which enable us to design the scope for our research study. Our research process is uniquely designed with enough flexibility to adjust according to changing nature of products and markets, while retaining core element to ensure reliability and accuracy in research findings. We understand both macro and micro-economic factors to evaluate and forecast different market segments.
Data Mining
Data is extensively collected through various secondary sources such as annual reports, investor presentations, SEC filings, and other corporate publications. We also refer trade magazines, technical journals, paid databases such as Factiva and Bloomberg, industry trade journals, scientific journals, and social media data to understand market dynamics and industry trends. Further, we also conduct primary research to understand market drivers, restraints, opportunities, challenges, and competitive scenario to build our analysis.
Data Collection Matrix
|
Data Collection Matrix |
Supply Side |
Demand Side |
|
Primary Data Sources |
|
|
|
Secondary Data Sources |
|
|
Market Modeling and Forecasting
We use epidemiology and capital equipment-based models to forecast market size of different segments at country and regional level.
- Epidemiology-based Forecasting Model: This method uses epidemiology data gathered through various publications and from physicians to estimate population of patients, flow of treatment of individual disease and therapies. The data collected through this method includes statics on incidence of disease, population suffering from disease, and treatment population. This method is used to understand:
- Number of patients for particular device or medical procedure and
- Repeated use of particular device depending on health and condition of patient
- Capital-based Forecasting Model: This method of forecasting is based on number of replacements, installed-based and new sales of capital equipment used in various healthcare and diagnostic centers. These three parameters are calculated and forecast is developed. Installation base is calculated as average number of units per facility; while sales for particular year is calculated from number of new and replace units. Secondary data is collected through various supply chain intermediaries and opinion leaders to arrive at installation and sales rate. These techniques help our analysts in validating market and developed market estimates and forecast.
We do forecast on basis of several parameters such as market drivers, market opportunities, industry trends government regulations, raw materials supply and trade dynamics to ensure relevance of forecast with market scenario. With increasing need to granulized information, we used bottom-up methodology for forecasting where we evaluate each regional segment differently and combined all forecast to develop final market forecast.
Data Validation
We believe primary research is a very important tool in analyzing and forecasting different markets. In order to make sure accuracy of our findings, our team conducts primary interviews at every stage of research to gain deep insights into current business environment and future trends and key developments in market. This includes use of various methods such as telephonic interviews, focus groups, face to face interviews and questionnaires to validate our research from all aspects. We validate our data through primary research from key industry leaders such as CEO, product managers, marketing managers, suppliers, distributors, and consumers are frequently interviewed. These interviews provide valuable insights which help us to have better market understanding besides validating our estimates and forecast.
Data Triangulation
Industry Analysis
|
Qualitative Data |
Quantitative Data (2017-2025) |
|
|